Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 767–768 | Cite as

ASO Author Reflections: Management of Malignant Peritoneal Mesothelioma

  • Taylor R. Cushman
  • Vivek Verma
  • Charles B. SimoneIIEmail author
ASO Author Reflections
  • 40 Downloads

Notes

Disclosures

Taylor R. Cushman, Vivek Verma, and Charles B. Simone II have no conflicts of interest to disclose.

References

  1. 1.
    Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20(6):935–44.CrossRefGoogle Scholar
  2. 2.
    Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26(21):3567–72.CrossRefGoogle Scholar
  3. 3.
    Brigand C, Monneuse O, Mohamed F, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13(3):405–12.CrossRefGoogle Scholar
  4. 4.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.CrossRefGoogle Scholar
  5. 5.
    Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686–93.CrossRefGoogle Scholar
  6. 6.
    Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol. 2018;25:2018–26.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Taylor R. Cushman
    • 1
  • Vivek Verma
    • 2
  • Charles B. SimoneII
    • 3
    Email author
  1. 1.University of Arizona College of Medicine–PhoenixPhoenixUSA
  2. 2.Department of Radiation OncologyAllegheny General HospitalPittsburghUSA
  3. 3.Department of Radiation Oncology, Maryland Proton Treatment CenterUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations